Creative Biolabs is a well-recognized expert professional in applying advanced drug development for a broad range of project objectives. With rich experience, our scientists can offer high-quality and custom services to meet our clients’ demands precisely.
Complement-directed Drug Development
The past few years have proven to be a highly successful and exciting period for the field of complement-directed drug discovery and development. Driven by promising experiences with the first marketed complement drugs, increased knowledge about the involvement of complement in health and disease, and improvements in structural and analytical techniques as well as animal models of disease, the field has seen a surge in creative approaches to therapeutically intervene at various stages of the cascade. Inhibition of complement activity is the desired outcome in the vast majority of therapeutic approaches, its local stimulation may be beneficial in some malignant diseases, such as cancer. Experience with monoclonal antibodies in cancer therapy suggests that induction of cell death through antibody-dependent cellular cytotoxicity or complement dependent cytotoxicity (CDC) may be a major driving force behind their effectiveness.
CD20 Antibody Development
In humans, CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues.
Fig. 1 The Structure of CD20.1
Example
Ofatumumab/HuMax-CD20 has been selected for clinical development and approved by FDA. Ofatumumab is a human mAb that targets an epitope encompassing the membrane-proximal small-loop on the CD20 molecule, which differs from the binding location of rituximab. In vitro studies with ofatumumab have demonstrated that it is significantly more effective than rituximab at corresponding dose levels at lysing CLL cells and B-cell lines, especially those with low CD20 copy numbers. However, this mAb also has been shown some adverse effects, like low respiratory tract, sepsis, agranulocytosis and so on.
Creative Biolabs has long-term devoted to the development of drugs for CD20. With years of experience, our scientists have developed drug discovery platform including drug design, expression, analysis, screening and so on. More than that, we can specifically tailor to boost our global customers’ research and project goal.
We are pleased to use our extensive experience and advanced platform to offer the best service and the most qualified products to satisfy each demand from our customers. If you are interested in using our drug development service for CD20, please contact us for more details.
Reference
1. From Wikipedia: commons: By Pleiotrope - Own work, https://commons.wikimedia.org/wiki/File:Protein_MS4A1_PDB_1S8B.png
Related Product
Questions & Answer
A: Creative Biolabs offers tailored drug development services, including the generation of CD20-specific antibodies, preclinical development support, and quality assurance. Our expertise ensures optimized therapeutic candidates with improved efficacy and safety profiles.
A: Specificity is crucial to targeted immunotherapy. We employ rigorous screening and validation techniques, including in vitro assays and animal models, to ensure CD20-targeted drugs selectively bind to B cells expressing CD20.
A: The future of CD20 drug development includes improved antibody engineering, personalized medicine approaches, and expanding applications beyond oncology to autoimmune diseases and transplantation medicine.
For Research Use Only.
Related Sections:
